U.S. markets closed

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7600-0.0100 (-0.36%)
At close: 04:00PM EST
2.7200 -0.04 (-1.45%)
After hours: 05:23PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.7700
Bid2.7200 x 4000
Ask2.7500 x 800
Day's Range2.6900 - 2.8900
52 Week Range1.8800 - 6.5000
Avg. Volume325,467
Market Cap144.017M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-1.0240
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,138.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NCNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NuCana plc
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more

    Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

    Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

  • GlobeNewswire

    NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update

    Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additional Encouraging Clinical Data for NUC-3373 and NUC-7738 at ESMO Multiple Near-Term Study Initiations and Data Announcements Expected EDINBURGH, United Kingdom, Nov. 18, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financia

  • GlobeNewswire

    NuCana to Present at the Jefferies 2021 London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference. Event: Jefferies 2021 London Healthcare ConferencePresentation Date: Wednesday, November 17, 2021Presentation Time: 4:20 PM GMT The presentation will be webcast live and available for replay under “Events & Presentatio